Pnd115 - A Comparison of Fda and Ema Guidance on Medicines for the Treatment of Alzheimer’s Disease

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2080
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Conference Report: US FDA/EMA Harmonization of Their Bioanalytical Guidance/Guideline and Activities of the Global Bioanalytical Consortium

Bioanalysis
PharmacologyAnalytical ChemistryMedical Laboratory TechnologyClinical BiochemistryMedicineToxicologyPharmaceutics
2012English

Correction To: FDA and EMA Biosimilar Approvals

Journal of General Internal Medicine
Internal Medicine
2019English

Herbal Medicines for the Treatment of Inflammatory Bowel Disease

Cochrane Database of Systematic Reviews
2014English

Treatment Recommendations to Cancer Patients in the Context of FDA Guidance for Next Generation Sequencing

BMC Medical Informatics and Decision Making
Health PolicyHealth Informatics
2019English

FDA Issues Draft Guidance on MRD Testing

Cancer Discovery
Oncology
2018English

Targeting Autophagy for the Treatment of Alzheimer’s Disease: Challenges and Opportunities

Frontiers in Molecular Neuroscience
Molecular NeuroscienceMolecular BiologyCellular
2019English

Alzheimer’s Disease and Intranasal Fluticasone Propionate in the FDA MedWatch Adverse Events Database

Journal of Alzheimer's Disease Reports
2018English

FDA Approval: Siltuximab for the Treatment of Patients With Multicentric Castleman Disease

Clinical Cancer Research
Cancer ResearchOncology
2015English

Evidence for a Lowered Threshold for FDA Approval of Oncologics Based on Single-Arm Phase II Data, Compared to the EMA

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy